Employees: 6
Size Mentari Therapeutics (MTRI) is a United States Industrials company (Miscellaneous Commercial Services) with a market value of $807M, the 2362nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $15.29 on 18 Nov 2026.
Performance Over six months the shares fell 90.5%, against -8.4% for the median peer and -2.2% for the United States market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue fell 82.9% over the last twelve months (peer median +6.4%); the operating margin is -1,238.6% (peer median 9.7%).
Valuation It trades at 982.9× enterprise value to sales against a peer median of 4.1× (most expensive of 20).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|---|
| Revenue | $820,188 | $0 | $0 | $4.60M | $4.14M |
| Revenue growth | — | — | -100% | +11% | — |
| Gross profit | -$589,717 | -$708,356 | -$532,328 | $496,395 | $1.14M |
| EBITDA | -$9.39M | -$9.19M | -$7.91M | -$7.53M | -$7.81M |
| Net income | -$13.2M | -$12.6M | -$8.16M | -$7.68M | -$7.95M |
| Free cash flow | -$8.16M | -$8.64M | -$8.10M | -$7.00M | -$7.44M |
| Capital expenditure | $0 | $0 | $0 | $9,293 | $160,014 |
| Total debt | $0 | $0 | $741,262 | $962,662 | $391,707 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | MTRI | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -88.6% | -5.3% | lowest of 21 |
| 6-month return | -90.5% | -8.4% | lowest of 21 |
| Distance from 52-week high | -93.4% | -31.3% | lowest of 21 |
| Revenue growth (TTM) | -82.9% | +6.4% | lowest of 21 |
| Operating margin | -1,238.6% | 9.7% | lowest of 21 |
| EV / Sales | 982.9× | 4.1× | most expensive of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Mentari Therapeutics MTRI | United States | $807M | -91% | -83% | -1,239% | 982.9× | n/a | n/a |
| BrightView BV | United States | $803M | -29% | +1% | 4% | 0.9× | n/a | n/a |
| Beijing Haitian Ruisheng Science Technology 688787.SS | China | $801M | -37% | +34% | 4% | 11.9× | n/a | n/a |
| transcosmos 9715.T | Japan | $814M | -11% | +6% | 4% | 0.2× | -18.2% | +3.2% |
| Karnov KAR.ST | Sweden | $820M | +9% | -4% | 20% | 4.1× | 5.1% | +27.9% |
| TaskUs TASK | United States | $827M | +50% | +9% | 12% | 0.9× | 1.3% | +19.9% |
| Anbang Save-Guard 603373.SS | China | $779M | +6% | -1% | 14% | 1.9× | 5.6% | +5.6% |
| Aimed Bio 0009K0.KS | South Korea | $778M | -61% | +228% | 34% | 13.8× | 10.2% | +652.2% |
| Beyondsoft 002649.SZ | China | $769M | -14% | -6% | 2% | 0.6× | 7.0% | +9.2% |
| Daqian Ecology & Environment 603955.SS | China | $769M | +21% | +217% | -53% | 14.7× | n/a | n/a |
| Shaanxi Fenghuo Electronics 000561.SZ | China | $851M | -27% | +8% | -26% | 4.1× | n/a | n/a |
| Omat Advanced Materials (Guangdong) 688530.SS | China | $757M | -19% | +82% | 9% | 5.7× | n/a | n/a |
| IP Group plc IPO.L | United Kingdom | $865M | +11% | -37% | 51% | 15.5× | n/a | n/a |
| Xi'an High Voltage Apparatus Research Institute 688334.SS | China | $866M | -11% | +4% | 29% | 4.5× | -2.9% | +20.3% |
| AXISCADES Technologies AXISCADES.NS | India | $871M | -6% | +5% | 10% | 7.4× | n/a | n/a |
| IBEX IBEX | United States | $744M | +79% | +15% | 9% | 1.1× | 1.0% | +7.7% |
| NOMURA 9716.T | Japan | $880M | +7% | -10% | 7% | 0.6× | -7.5% | +8.6% |
| Funshine Culture 300860.SZ | China | $739M | 0% | -49% | -35% | 10.1× | 21.5% | -24.6% |
| Shandong Link Science and Technology 001207.SZ | China | $733M | -24% | +7% | 13% | 1.7× | -5.5% | +18.9% |
| Cuscal CCL.AX | Australia | $728M | +17% | +19% | 12% | n/a | n/a | n/a |
| Shenzhen Boshijie Technology 301608.SZ | China | $896M | -31% | +15% | 14% | 2.5× | n/a | n/a |